NOTV Stock Overview
Provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Inotiv, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.90 |
| 52 Week High | US$11.42 |
| 52 Week Low | US$1.23 |
| Beta | 3.37 |
| 11 Month Change | 119.10% |
| 3 Month Change | 167.12% |
| 1 Year Change | 38.30% |
| 33 Year Change | -91.14% |
| 5 Year Change | -14.29% |
| Change since IPO | -52.73% |
Recent News & Updates
Recent updates
Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues
Apr 26
Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt
Mar 19Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Feb 13Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company
Dec 18Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81
Dec 13Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Nov 21Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Aug 14Is Inotiv (NASDAQ:NOTV) Using Debt In A Risky Way?
May 09Inotiv adds 16% on settlement with U.S. over Virginia facility
Jul 18Inotiv completes acquisition of bioanalytical company Protypia for ~$11M
Jul 07Headwaters Capital - Inotiv: Transformation Into A Critical Full-Service Contract Research Organization
May 25Inotiv: Leading Mid-Market CRO Ups Its Game
Feb 07Shareholder Returns
| NOTV | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 4.0% | 1.8% | 0.7% |
| 1Y | 38.3% | 4.5% | 32.2% |
Return vs Industry: NOTV exceeded the US Life Sciences industry which returned 4% over the past year.
Return vs Market: NOTV exceeded the US Market which returned 31.9% over the past year.
Price Volatility
| NOTV volatility | |
|---|---|
| NOTV Average Weekly Movement | 15.8% |
| Life Sciences Industry Average Movement | 9.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NOTV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NOTV's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1974 | 2,005 | Bob Leasure | www.inotivco.com |
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company’s BASi product line.
Inotiv, Inc. Fundamentals Summary
| NOTV fundamental statistics | |
|---|---|
| Market cap | US$95.17m |
| Earnings (TTM) | -US$99.22m |
| Revenue (TTM) | US$501.06m |
0.2x
P/S Ratio-1.0x
P/E RatioIs NOTV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOTV income statement (TTM) | |
|---|---|
| Revenue | US$501.06m |
| Cost of Revenue | US$388.00m |
| Gross Profit | US$113.06m |
| Other Expenses | US$212.28m |
| Earnings | -US$99.22m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Dec 03, 2024
| Earnings per share (EPS) | -3.82 |
| Gross Margin | 22.56% |
| Net Profit Margin | -19.80% |
| Debt/Equity Ratio | 210.0% |
How did NOTV perform over the long term?
See historical performance and comparison